Botanix Conference Commercial Update
| Stock | Botanix Pharmaceuticals Ltd (BOT.ASX) |
|---|---|
| Release Time | 11 Mar 2025, 8:23 a.m. |
| Price Sensitive | Yes |
Botanix Announces Commercial Update for Sofdra Launch
- New chemical entity to treat primary axillary hyperhidrosis in adults and children 9 years and older
- Highly experienced team with successful track record in dermatology commercialization
- Large market opportunity with 10M hyperhidrosis patients, targeting 3.7M seeking treatment
Botanix Pharmaceuticals Ltd. has provided a commercial update on the launch of its new treatment for primary axillary hyperhidrosis, Sofdra. The company has assembled a highly experienced team with a proven track record of successful dermatology commercialization, including executives from Dermavant, Anacor, and Medicis. Sofdra is the first and only new chemical entity approved to treat primary axillary hyperhidrosis in adults and children 9 years of age and older. The company is well-capitalized with approximately A$48 million to fund the commercial launch and platform development. Botanix is targeting the 3.7 million patients seeking treatment for hyperhidrosis, as well as activating a small percentage of the other 6.3 million patients who have the condition but are not currently seeking treatment. The company's strategy involves driving demand with a targeted sales force, providing seamless fulfillment and refills through a patient concierge service, and launching a full digital campaign to engage patients and healthcare providers.The Sofdra commercial launch is underway, with the sales team performing on target and the digital launch expected to add further prescription volume. Botanix is focused on maximizing payer coverage and pricing, educating dermatologists, engaging patients through telemedicine, and ensuring a smooth fulfillment process to drive commercial success.
Botanix is targeting the 3.7 million patients seeking treatment for hyperhidrosis, as well as activating a small percentage of the other 6.3 million patients who have the condition but are not currently seeking treatment.
Botanix is well-capitalized with approximately A$48 million to fund the commercial launch and platform development. The company's strategy involves driving demand with a targeted sales force, providing seamless fulfillment and refills through a patient concierge service, and launching a full digital campaign to engage patients and healthcare providers.